Sun Pharma gets exclusive right to commercialize Winlevi in US, Canada
1st Sep 2021

Sun Pharmaceutical Industries has the exclusive right to commercialize Winlevi in the US and Canada. Cassiopea will be the exclusive supplier of the product, which is expected to be available in the US in the fourth quarter of 2021. The expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) clears the path for making Winlevi available to patients and healthcare providers in the US and Canada.

With Winlevi, a unique product with a new mechanism of action for the topical treatment of acne vulgaris, the company has further expanded our basket of innovative products to serve patients better. The US Food and Drug Administration (USFDA) approved Winlevi (clascoterone cream 1 percent) in August 2020 for the topical treatment of acne vulgaris in patients 12 years and older.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.